Literature DB >> 29415784

PEER-REVIEWED JOURNAL EDITORS' VIEWS ON REAL-WORLD EVIDENCE.

Elisabeth M Oehrlein1, Jennifer S Graff2, Eleanor M Perfetto3, C Daniel Mullins4, Robert W Dubois2, Chinenye Anyanwu4, Eberechukwu Onukwugha4.   

Abstract

OBJECTIVES: Peer-review publication is a critical step to the translation and dissemination of research results into clinical practice guidelines, health technology assessment (HTA) and payment policies, and clinical care. The objective of this study was to examine current views of journal editors regarding: (i) The value of real-world evidence (RWE) and how it compares with other types of studies; (ii) Education and/or resources journal editors provide to their peer reviewers or perceive as needed for authors, reviewers, and editors related to RWE.
METHODS: Journal editors' views on the value of RWE and editorial procedures for RWE manuscripts were obtained through telephone interviews, a survey, and in-person, roundtable discussion.
RESULTS: In total, seventy-nine journals were approached, resulting in fifteen telephone interviews, seventeen survey responses and eight roundtable participants. RWE was considered valuable by all interviewed editors (n = 15). Characteristics of high-quality RWE manuscripts included: novelty/relevance, rigorous methodology, and alignment of data to research question. Editors experience challenges finding peer reviewers; however, these challenges persist across all study designs. Journals generally do not provide guidance, assistance, or training for reviewers, including for RWE studies. Health policy/health services research (HSR) editors were more likely than specialty or general medicine editors to participate in this study, potentially indicating that HSR researchers are more comfortable/interested in RWE.
CONCLUSIONS: Editors report favorable views of RWE studies provided studies examine important questions and are methodologically rigorous. Improving peer-review processes across all study designs, has the potential to improve the evidence base for decision making, including HTA.

Entities:  

Keywords:  Decision Making*; Editorial policies; Epidemiologic research design; Observational studies as topic*; Peer review; Research/standards

Mesh:

Year:  2018        PMID: 29415784     DOI: 10.1017/S0266462317004408

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  4 in total

Review 1.  Delivering precision oncology to patients with cancer.

Authors:  Joaquin Mateo; Lotte Steuten; Philippe Aftimos; Fabrice André; Mark Davies; Elena Garralda; Jan Geissler; Don Husereau; Iciar Martinez-Lopez; Nicola Normanno; Jorge S Reis-Filho; Stephen Stefani; David M Thomas; C Benedikt Westphalen; Emile Voest
Journal:  Nat Med       Date:  2022-04-19       Impact factor: 87.241

2.  Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare.

Authors:  Denis Horgan; Bettina Borisch; Ivana Cattaneo; Mark Caulfield; Arturo Chiti; Christine Chomienne; Amanda Cole; Karen Facey; Allan Hackshaw; Minna Hendolin; Nadia Georges; Dipak Kalra; Birutė Tumienė; Martina von Meyenn
Journal:  Int J Environ Res Public Health       Date:  2022-02-01       Impact factor: 3.390

3.  Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust.

Authors:  Elisabeth M Oehrlein; Jennifer S Graff; Jason Harris; Eleanor M Perfetto
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

4.  Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.

Authors:  Denis Horgan; Giuseppe Curigliano; Olaf Rieß; Paul Hofman; Reinhard Büttner; Pierfranco Conte; Tanja Cufer; William M Gallagher; Nadia Georges; Keith Kerr; Frédérique Penault-Llorca; Ken Mastris; Carla Pinto; Jan Van Meerbeeck; Elisabetta Munzone; Marlene Thomas; Sonia Ujupan; Gilad W Vainer; Janna-Lisa Velthaus; Fabrice André
Journal:  J Pers Med       Date:  2022-01-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.